Eli Lilly said weight-loss demand didn't grow as fast as it had hoped

Eli Lilly (LLY) revised its revenue outlook on Tuesday for the fourth quarter of 2024 on weaker-than-expected demand for its popular weight-loss drugs, Zepbound and Mounjaro.Read more...

featured-image

ONLY AVAILABLE IN PAID PLANS.